Bioline RX Ltd  

(Public, NASDAQ:BLRX)   Watch this stock  
Find more results for BLRX
+0.08 (6.11%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.28 - 1.60
52 week 1.03 - 3.28
Open 1.33
Vol / Avg. 0.00/205,210.00
Mkt cap 75.97M
P/E     -
Div/yield     -
EPS -1.21
Shares 54.65M
Beta 1.80
Inst. own     -
Jan 10, 2016
BioLineRx to present at Biotech Showcase in San Francisco, CA January 11-13, 2016 - 7:00PM EST - Add to calendar
Jan 10, 2016
BioLineRx to attend the 34rd Annual JP Morgan Healthcare Conference - 7:00PM EST - Add to calendar
Dec 1, 2015
BiolineRx will present at the LD Micro Main Event in Los Angeles, CA on December 2, 2015 - 7:00PM EST - Add to calendar
Nov 16, 2015
Q3 2015 BioLine RX Ltd Earnings Call
Nov 16, 2015
Q3 2015 BioLine RX Ltd Earnings Release
Nov 2, 2015
BioLine RX Ltd at �EBD BIO Europe- Fall
Sep 9, 2015
BioLine RX Ltd at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    


19 Hartum Street, P.O.Box 45158
+972-2-5489100 (Phone)
+972-2-5489101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Officers and directors

Aharon Schwartz Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Kinneret Savitsky Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Philip Adam Serlin Chief Financial Officer, Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Moshe Phillip M.D. Vice President of Medical Affairs and Senior Clinical Advisor
Age: 59
Bio & Compensation  - Reuters
David Malek Vice President - Business Development
Age: 35
Bio & Compensation  - Reuters
Leah Klapper General Manager, BioLine Innovations Jerusalem
Bio & Compensation  - Reuters
Michael J. Anghel Director
Age: 76
Bio & Compensation  - Reuters
Jacob Friedman Director
Age: 44
Bio & Compensation  - Reuters
Raphael Hofstein Director
Age: 63
Bio & Compensation  - Reuters
Sandra Panem Ph.D. Director
Age: 68
Bio & Compensation  - Reuters